Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation
Patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) require indwelling central venous catheters. The comparative incidence, risk, and outcome of isolated catheter-related deep venous thrombosis (CR-DVT) versus pulmonary embolism/lower-extremity DVT (PE/LE-DVT) remains unclear. (Source: Thrombosis Research)
Source: Thrombosis Research - June 15, 2023 Category: Hematology Authors: Jonathan Avery, Danielle Guffey, Shengling Ma, Ryan Basom, Stephanie J. Lee, David Garcia, Cristhiam M. Rojas Hernandez, Ang Li, Kylee L. Martens Tags: Full Length Article Source Type: research
Barriers and facilitators for adherence to direct oral anticoagulants in patients with atrial fibrillation: A qualitative approach
Direct oral anticoagulants (DOACs) are the cornerstone for stroke prevention in patients with atrial fibrillation (AF) [1]. DOAC non-adherence and discontinuation have been associated with higher thromboembolic and mortality risks [2]. Until now, studies trying to optimise adherence to DOACs show disappointing results with limited effectiveness of interventions [3]. An explanation might be that medication (non-)adherence is a very complex behaviour in which different determinants, varying between patients, play a role. (Source: Thrombosis Research)
Source: Thrombosis Research - June 14, 2023 Category: Hematology Authors: Andreas Capiau, Maxim Grymonprez, Sophie Scheire, Yenna Faute, Lies Lahousse, Els Mehuys, Tine De Backer, Koen Boussery Tags: Letter to the Editors-in-Chief Source Type: research
Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination
Reported thromboembolic events after SARS-CoV-2 vaccinations are still raising concerns, predominantly in non-scientific population. The aim of our study was to investigate the differences between haemostasis and inflammatory markers in the subjects vaccinated with mRNA BNT162b2 and vector Ad26.CoV2.S vaccine. (Source: Thrombosis Research)
Source: Thrombosis Research - June 13, 2023 Category: Hematology Authors: I. Ivanko, I. Ćelap, S. Margetić, D. Marijančević, J. Josipović, P. Gaćina Tags: Full Length Article Source Type: research
Using an age and fibrinogen levels adjusted D-dimer cutoff significantly improves the specificity of two equivalent D-dimer assays for excluding pulmonary embolism
Our single-center prospective study compared two methods of D-dimer determination used in the exclusion of pulmonary embolism: bioM érieux method, VIDAS® D-Dimer Exclusion™ II, and Diagnostica Stago method, STA®-Liatest® D-Di Plus. For each of these two methods, we calculated optimized variable cutoffs based on fibrinogen and/or age to improve the specificity of the methods. (Source: Thrombosis Research)
Source: Thrombosis Research - June 13, 2023 Category: Hematology Authors: Simon Jaouen, Fanny Mingant, Eric Lippert, Hubert Galinat Tags: Full Length Article Source Type: research
Bleeding outcomes and management of supratherapeutic episodes secondary to warfarin in children: A single center 10-year experience
Ventricular assist device (Source: Thrombosis Research)
Source: Thrombosis Research - June 13, 2023 Category: Hematology Authors: Clay T. Cohen, Mark Zobeck, HyoJeong Han, Joseph A. Spinner, Jacquelyn M. Powers, YoungNa Lee-Kim, Sarah E. Sartain Tags: Letter to the Editors-in-Chief Source Type: research
The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists
The European Medicine Agency has authorized COVID-19 vaccination in adolescents and young adults (AYAs) from 12 years onwards. In elderly vitamin K antagonist (VKA) users, COVID-19 vaccination has been associated with an increased risk of supra- and subtherapeutic INRs. Whether this association is also observed in AYAs using VKA is unknown. Our aim was to describe the stability of anticoagulation after COV ID-19 vaccination in AYA VKA users. (Source: Thrombosis Research)
Source: Thrombosis Research - June 11, 2023 Category: Hematology Authors: Chantal Visser, Arjen Yousefi, Melchior C. Nierman, Menno V. Huisman, Anouk J.W. Gulpen, C. Heleen van Ommen, Marieke J.H.A. Kruip, Dutch COVID and Thrombosis Coalition Tags: Full Length Article Source Type: research
Risk of midline catheter-related thrombosis due to catheter diameter: An observational cohort study
Deep vein thrombosis is a common and serious complication associated with midline catheters (MC). The aim of this investigation was to determine if catheter diameter is related to development of thrombosis. (Source: Thrombosis Research)
Source: Thrombosis Research - June 11, 2023 Category: Hematology Authors: Amit Bahl, Nicholas Mielke, Yuying Xing Tags: Full Length Article Source Type: research
Polygenic risk scores and risk stratification in deep vein thrombosis
Deep vein thrombosis (DVT) is a complex disease, where 60 % of risk is due to genetic factors, such as the Factor V Leiden (FVL) variant. DVT is either asymptomatic or manifests with unspecific symptoms and, if left untreated, DVT leads to severe complications. The impact is dramatic and currently, there is still a research gap in DVT prevention. We cha racterized the genetic contribution and stratified individuals based on genetic makeup to evaluate if it favorably impacts risk prediction. (Source: Thrombosis Research)
Source: Thrombosis Research - June 10, 2023 Category: Hematology Authors: Valeria Lo Faro, Therese Johansson, Julia H öglund, Fatemeh Hadizadeh, Åsa Johansson Tags: Full Length Article Source Type: research
Management of anticoagulation in patients with infective endocarditis
Infective endocarditis (IE) carries a high risk of vascular complications (e.g., cerebral embolism, intracerebral hemorrhage, and renal infarction), which are correlated with increased early and late mortality. Although anticoagulation is the cornerstone for management of thromboembolic complications, it remains controversial and challenging in patients with IE. An appropriate anticoagulation strategy is crucial to improving outcomes and requires a good understanding of the indication, timing, and regimen of anticoagulation in the setting of IE. (Source: Thrombosis Research)
Source: Thrombosis Research - June 10, 2023 Category: Hematology Authors: Xiaogang Zhu, Zhenhua Wang, Markus W. Ferrari, Katharina Ferrari-Kuehne, David H. Hsi, Gary Tse, Quanzhong Zhou, Haifeng Liang, Yuhui Zhang, Jian Zhang Tags: Review Article Source Type: research
Screening for thrombophilia in patients with thromboangitis obliterans using whole-exome sequencing
The aetiology of Thromboangitis obliterans (TAO) is not well understood. There is disagreement on the inclusion of thrombophilia in a TAO diagnosis, and no internationally accepted diagnostic criteria have been established. Of the four main diagnostic criteria for TAO, Olin's criteria and Mills' criteria describe hypercoagulable states as exclusion criteria, but Shionoya's criteria and Papa's criteria do not [1]. Additionally, during the 2022 International Delphi Consensus, there was disagreement among experts on using thrombophilia as an exclusion criterion [1]. (Source: Thrombosis Research)
Source: Thrombosis Research - June 7, 2023 Category: Hematology Authors: Feng Chen, Zhi Ru Chen, Wei Zhou Tags: Letter to the Editors-in-Chief Source Type: research
Contemporary trends in mortality related to high-risk pulmonary embolism in US from 1999 to 2019
Population-based data on high-risk pulmonary embolism (PE) mortality trends in the United States (US) are scant. (Source: Thrombosis Research)
Source: Thrombosis Research - June 5, 2023 Category: Hematology Authors: Marco Zuin, Behnood Bikdeli, Julia Davies, Darsiya Krishnathasan, Gianluca Rigatelli, Loris Roncon, Claudio Bilato, Gregory Piazza Tags: Full Length Article Source Type: research
Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients
The protein tyrosine phosphatase SHP2 (PTPN11) is a negative regulator of glycoprotein VI (GPVI)-induced platelet signal under certain conditions. Clinical trials with derivatives of the allosteric drug SHP099, inhibiting SHP2, are ongoing as potential therapy for solid cancers. Gain-of-function mutations of the PTPN11 gene are observed in part of the patients with the Noonan syndrome, associated with a mild bleeding disorder. Assessment of the effects of SHP2 inhibition in platelets from controls and Noonan syndrome patients. (Source: Thrombosis Research)
Source: Thrombosis Research - June 5, 2023 Category: Hematology Authors: Delia I. Fern ández, Marije Diender, Lidia Hermida-Nogueira, Jingnan Huang, Sonia Veiras, Yvonne M.C. Henskens, Maroeska W.M. te Loo, Johan W.M. Heemskerk, Marijke J.E. Kuijpers, Ángel García Source Type: research
Incidence of recurrent venous thromboembolism and bleeding complications in patients with cancer and isolated distal deep vein thrombosis
Isolated distal deep vein thrombosis (IDDVT) is a common clinical presentation of DVT. The efficacy and safety of anticoagulant therapy for the management of IDDVT in patients with cancer are unclear. We sought to assess the incidence of recurrent venous thromboembolism (VTE) and major bleeding in this patient population. (Source: Thrombosis Research)
Source: Thrombosis Research - June 3, 2023 Category: Hematology Authors: Cameron Brown, Willem Brandt, Tzu-Fei Wang, Aur élien Delluc, Marc Carrier Tags: Full Length Article Source Type: research
Immature platelet dynamics in management of protracted response to therapy of a young pediatric patient with immune-mediated thrombotic thrombocytopenic purpura
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) represents an emergent clinical presentation that can lead to significant morbidity and potentially mortality if left untreated. Diagnosis of iTTP is dependent upon establishing deficiency in the enzyme ADAMTS13 ( ≤10 %), that in most cases is due to autoantibody formation [1]. These inhibitory autoantibodies prevent ADAMTS13 function leading to accumulation of ultra-large molecular weight von Willebrand Factor multimers, diffuse microvascular thrombi formation and consequently severe thrombocytopenia [2] . (Source: Thrombosis Research)
Source: Thrombosis Research - June 3, 2023 Category: Hematology Authors: Robert W. Maitta, Hollie M. Reeves, Katharine A. Downes, Xiangrong He, Lisa R. Hackney, Sanjay P. Ahuja Tags: Letter to the Editors-in-Chief Source Type: research
Clinical effectiveness and safety of edoxaban in obese patients — Results of the prospective Dresden NOAC Registry (NCT01588119)
Edoxaban is a direct factor Xa inhibitors approved for stroke prevention in atrial fibrillation (SPAF) and for venous thromboembolism (VTE) treatment. Edoxaban is given in a fixed dosing regimen (with recommended dose reductions for patients with renal impairment or body weight (Source: Thrombosis Research)
Source: Thrombosis Research - June 2, 2023 Category: Hematology Authors: Luise Tittl, Christina K öhler, Sandra Marten, Christiane Naue, Kristina Fache, Laura Stanneck, Thomas Schreier, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research
